Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002)

在 2a 期随机、剂量范围、对照试验 (AI468002) 中，评估了第二代人类免疫缺陷病毒 1 型成熟抑制剂 GSK3532795 作为单药治疗或与阿扎那韦联合治疗（含或不含利托那韦）的抗病毒活性、安全性和暴露-反应关系。